BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37189003)

  • 1. Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910.
    Shida D; Kuchiba A; Shibata T; Hamaguchi T; Yamasaki S; Ito M; Kobatake T; Tonooka T; Masaki T; Shiozawa M; Takii Y; Uetake H; Okamura S; Ojima H; Kazama S; Takeyama H; Kanato K; Shimada Y; Murakami Y; Kanemitsu Y
    Cancer Sci; 2023 Aug; 114(8):3352-3363. PubMed ID: 37189003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial/Ethnic and Sex Differences in Somatic Cancer Gene Mutations among Patients with Early-Onset Colorectal Cancer.
    Holowatyj AN; Wen W; Gibbs T; Seagle HM; Keller SR; Edwards DRV; Washington MK; Eng C; Perea J; Zheng W; Guo X
    Cancer Discov; 2023 Mar; 13(3):570-579. PubMed ID: 36520636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
    Escobar D; Bushara O; Sun L; Liao J; Yang GY
    Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
    Popovici V; Budinska E; Bosman FT; Tejpar S; Roth AD; Delorenzi M
    BMC Cancer; 2013 Sep; 13():439. PubMed ID: 24073892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer.
    Mouradov D; Greenfield P; Li S; In EJ; Storey C; Sakthianandeswaren A; Georgeson P; Buchanan DD; Ward RL; Hawkins NJ; Skinner I; Jones IT; Gibbs P; Ma C; Liew YJ; Fung KYC; Sieber OM
    Gastroenterology; 2023 Jul; 165(1):104-120. PubMed ID: 36933623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer.
    Lee SE; Park HY; Hwang DY; Han HS
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.
    Baratti D; Kusamura S; Niger M; Perrone F; Milione M; Cattaneo L; Guaglio M; Bartolini V; Pietrantonio F; Deraco M
    Ann Surg Oncol; 2021 Jun; 28(6):3332-3342. PubMed ID: 32974694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
    van den Broek E; Krijgsman O; Sie D; Tijssen M; Mongera S; van de Wiel MA; Belt EJ; den Uil SH; Bril H; Stockmann HB; Ylstra B; Carvalho B; Meijer GA; Fijneman RJ
    Oncotarget; 2016 Nov; 7(45):73876-73887. PubMed ID: 27729614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer.
    Tran CG; Goffredo P; Mott SL; Hart A; You YN; Vauthey JN; Weigel RJ; Hassan I
    Surgery; 2022 Mar; 171(3):657-665. PubMed ID: 34865865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Study.
    Chibaudel B; André T; Tournigand C; Louvet C; Benetkiewicz M; Larsen AK; de Gramont A
    Clin Colorectal Cancer; 2020 Sep; 19(3):200-208.e1. PubMed ID: 32303437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
    Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
    Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
    Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
    J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.